ClinicalTrials.gg
RecruitingNCT03590171Updated Mar 17, 2026

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

A Phase 2 interventional study of Bortezomib in Acute Lymphoblastic Leukemia (ALL), sponsored by Charite University, Berlin, Germany. Recruiting at 15 sites in 15 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Charite University, Berlin, Germany · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2017, registered May 2018).
  • Started Sep 2017; still recruiting 9 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing bortezomib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 8 under way, 3 of them phase 3. Bortezomib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
5th of 33
250 · median 36
Started
2017
with 2 others
Phase 2
13 of 36
3 open now
Registered
30th of 36
by date
Lead sponsor
1 of 36
Charite University, Berlin, Germany

Among the 36 studies testing bortezomib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2017, is one of 13 in phase 2, and was the 30th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 36 studies testing bortezomib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing bortezomib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

Read the detailed description

Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Risk has been defined by the International (I) Berlin, Frankfurt, Münster (BFM) Study Group (SG) based on duration of first remission, immunophenotype of malignant clone, and site of relapse. Patients classified as high risk (HR) by these criteria have poor response rates to standard induction therapy, high rates of subsequent relapse and require an allogeneic hematopoetic stem cell transplantation (allo-HSCT) for consolidation of 2nd remission. Over the last decade members of the I-BFM-SG have investigated the use of different combinations of conventional cytotoxic agents. Even with allo-HSCT, none of these approaches have improved outcome above 40%. Therefore, for HR patients there is a need to investigate the curative potential of new agents combined with systemic therapy. The proteasome inhibitor bortezomib has shown synergistic activity with acceptable toxicity when combined with corticosteroids, anthracyclines and alkylating agents in adult patients with cancer as well as with dexamethasone, doxorubicin, vincristine and polyethylene glycol (PEG) asparaginase in children with refractory or relapsed ALL. In the I-BFM-SG International Study for Treatment of High Risk Childhood Relapsed ALL (IntReALL) HR 2010 study, the potential of Bortezomib combined with a modified ALL relapse protocol 3 (R3) backbone as induction regimen for HR patients to improve complete 2nd remission (CR2) rates will be investigated in a randomized phase II design. Induction is followed by conventional intensive consolidation. After termination of the trial patients may be subjected to an investigational window, before all of them receive allo-HSCT.

03

Conditions studied

  • Acute Lymphoblastic Leukemia (ALL)

Keywords

  • ALL
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Morphologically confirmed diagnosis of 1st precursor B-cell or T-cell ALL
  • Children less than 18 years of age at date of inclusion into the study
  • Meeting HR criteria any BM relapse, early/very early isolated BM relapse, very early isolated/combined extramedullary relapse)
  • Patient enrolled in a participating centre
  • Written
  • Start of treatment falling into the study period
  • No participation in other clinical trials 30 day prior to study enrolment that interfere with this protocol, except trials for primary ALL

Exclusion criteria

Exclusion Criteria:

  • Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
  • Pregnancy or positive pregnancy test (urine sample positive for β-humane choriongonadotropin (HCG) > 10 U/l)
  • Sexually active adolescents not willing to use highly effective method (pearl index \<1) until 12 months after end of anti-leukemic therapy
  • Breast feeding
  • Relapse post stem-cell transplantation
  • Neuropathy > II°
  • The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
  • Objection to the study participation by a minor patient, able to object
  • Any patient being dependent on the investigator
  • No consent is given for saving and propagation of pseudonymized medical data for study reasons
  • Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders)
  • Subjects unwilling or unable to comply with the study procedures
  • Subjects who are legally detained in an official institute
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • No intervention
    Arm HR-A

    Induction: Backbone ALL R3

  • Experimental
    Arm HR-B

    Induction: Backbone ALL R3 + Bortezomib

    Drug: Bortezomib

Interventions

  • Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.

06

What researchers measure

Primary outcomes

  1. Rate of Complete Remission

    Rate of complete second remission (CR2) quantified by cytology after induction with standard chemotherapy + bortezomib (arm B) compared with standard chemotherapy (arm A).

    Time frame: Week 4

Secondary outcomes

  1. Event-free Survival

    Improvement of three years event-free survival (EFS)

    Time frame: Year 3

  2. Overall Survival

    Improvement of three years overall survival (OS)

    Time frame: Year 3

  3. Minimal Residual Disease Reduction (MRD)

    Improvement of Minimal Residual Disease (MRD) reduction after induction with versus without bortezomib

    Time frame: Week 4

  4. Minimal Residual Disease Load

    Improvement of MRD load prior to stem cell transplantation (SCT).

    Time frame: Week 15

  5. Minimal Residual Disease (MRD)

    Prognostic relevance of MRD pre stem cell transplantation (SCT). MRD will be quantified before stem cell transplantation with polymerase chain reaction (PCR) and will be related to EFS after SCT. Multicolour flow cytometry will be used in parallel with PCR. Flow cytometry is used instead of PCR if PCR based MRD-quantification cannot be performed, because criteria for a reliable and reproducible sensitive quantification are not fulfilled.

    Time frame: Week 15

  6. Complete Remission/Minimal Residual Disease Rates During Consolidation

    Improvement of CR2 and/or MRD rates during consolidation

    Time frame: Week 5, 8, 11, 15

  7. Toxicity of induction classified with the COMMON TOXICITY CRITERIA (CTC)

    Toxicity of induction with versus without bortezomib. Toxicity of the central nervous system and peripheral neuropathy will be classified with the COMMON TOXICITY CRITERIA (CTC).

    Time frame: At induction up to week 5

Other outcomes

  1. Minimal Residual Disease in Isolated Extramedullary Relapse

    The rate and extent of sub-microscopic bone marrow (BM) involvement in extramedullary leukemia will be investigated prospectively.

    Time frame: Day 0; Week 5, 8, 11, 15

  2. Extended Genetic Characterization

    Extension of genetic characterization and correlation with clinical data

    Time frame: Day 0

  3. In-vitro drug response profile

    Generation of primografts from patient samples for bio-banking and drug testing by using immunodeficient mice. The outcome measure is the in-vitro drug response profile using the primograft of primary patient sample. The in-vitro drug response profile will be compared to the in-vivo drug response of a patient. In order to get an "in-vitro drug response profile" apoptosis/viability of the primary patient sample or patient-derived xenograft sample is measured using different concentrations of novel drugs normally after 48 hours of treatment. These drugs could be potentially given to a patient, when there will be no response to conventional protocol treatment. Apoptosis/viability is measured by live cell imaging microscopy or/and by flow cytometry. The report will include half maximal inhibitory concentration (IC50), the concentration of a drug which kills half of the cell after a defined time (normally 48h) for a variety of potential drugs.

    Time frame: Day 0

07

Study locations

10 of 15 sites recruiting
  • Australian & New Zealand Childhood Hematology & Oncology Group
    Clayton, Victoria 3168, Australia
    Recruiting
    • Tamas Revesz, MD · Contact
  • St. Anna Kinderkrebsforschung, CCRI
    Vienna, 1090, Austria
    Recruiting
    • Georg Mann, MD · Contact
    • Andishe Atterbashi, MD · Contact
  • Hòpital Universitaire des Enfants Reine Fabiola
    Brussels, 1020, Belgium
    Recruiting
    • Alina Ferster, MD · Contact
  • University Hospital Motol
    Prague, Czechia
    Recruiting
    • Lucie Sramkova, MD · Contact
  • Copenhagen University Hospital (Rigshospitalet)
    Copenhagen, 2100, Denmark
    Not yet recruiting
    • Thomas Frandsen, MD · Contact
  • Turku University Central Hospital
    Turku, SF-20520, Finland
    Recruiting
    • Päivi Lähteenmäki, MD · Contact
  • CHU Nice
    Nice, France
    Recruiting
    • Pierre Rohrlich, MD · Contact
  • Tel Aviv Sourasky Medical Centre
    Tel Aviv, 64239, Israel
    Recruiting
    • Ronit Elhasid, MD · Contact
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
    Recruiting
    • Franco Locatelli, MD · Contact
  • Prinses Máxima Centrum, Lundlaan
    Utrecht, Netherlands
    Recruiting
    • Peter Hoogerbrugge, MD · Contact
  • Oslo University Hospital
    Oslo, 0027, Norway
    Not yet recruiting
    • Marit Hellebostad, MD · Contact
  • Dpt. SCT and Hematology/Oncology University Wroclaw
    Wroclaw, 50354, Poland
    Recruiting
    • Ewa Goczynska, MD · Contact
  • Instituto Português de Oncologia de Lisboa
    Lisbon, Portugal
    Not yet recruiting
    • Joaquin Duarte, MD · Contact
  • University Hospital Stockholm
    Stockholm, 17176, Sweden
    Not yet recruiting
    • Petter Svenberg, MD · Contact
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
    Not yet recruiting
    • Denise Bonney, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2027, 123 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 123 months is above that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2018
First posted
Jul 18, 2018
StartActual
Sep 1, 2017
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03590171
Collaborators
Australian & New Zealand Children's Haematology/Oncology Group, St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria), European Organisation for Research and Treatment of Cancer - EORTC, University Hospital, Motol, Rigshospitalet, Denmark, Turku University Central Hospital (co-sponsor, Finland), Centre Hospitalier Universitaire de Nice, Our Lady's Chilrden's Hospital (Co-Sponsor Ireland), Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel), Ospedale Pediatrico Bambino (co-sponsor, Italy), Prinses Máxima Centrum (Co-Sponsor Netherlands), Oslo University Hospital (co-sponsor, Norway), Wroclaw Medical University, Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal), Karolinska University Hospital Stockholm (co-sponsor, Sweden), Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain), University Children's Hospital, Zurich, Manchester University NHS Foundation Trust
Responsible party
PD Dr. Arend von Stackelberg (Prinicipal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
Jul 18, 2018
Start date
Sep 1, 2017
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Arend von Stackelberg, MD
Contact
arend.stackelberg@charite.de
+49(0)30-450666 ext. 833
Arend von Stackelberg, MD
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion